all the information, none of the junk | biotech • healthcare • life sciences

Tyme Technologies Taps Eckard for Chief Scientific Affairs Post

Xconomy New York — 

Tyme Technologies (NASDAQ: TYME) has appointed Jonathan Eckard chief scientific affairs officer. Eckard most recently worked as chief business and strategy officer for cancer drug developer Sellas Life Sciences. New York-based Tyme’s lead drug candidate, SM-88, is in early-stage testing as a potential prostate cancer treatment.